NYSE · ABBV
Healthcare · Drug Manufacturers - General
$266.69
Up+$4.67 (+1.75%)
Updated Oct 7, 2026, 8:54 PM
SID Score
7.0/10
Composite research score
Smart Money
59/100
Neutral
Price performance · ABBV
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
ABBV closed at $266.69 after 21 trading sessions, up 7.20% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $267.74 | $268.8582 | $260.6197 | $266.69 | 4.5M |
| Oct 5, 2026 | $261.27 | $267.34 | $260.29 | $265.76 | 7.54M |
| Oct 2, 2026 | $259.74 | $264.06 | $257.87 | $262.82 | 5.86M |
| Oct 1, 2026 | $260.51 | $262.3158 | $259.00 | $259.93 | 3.89M |
| Sep 30, 2026 | $264.60 | $265.36 | $261.59 | $261.59 | 4.39M |
| Sep 29, 2026 | $265.45 | $268.93 | $261.5213 | $263.29 | 4M |
| Sep 28, 2026 | $264.33 | $267.735 | $263.38 | $266.28 | 4.43M |
| Sep 25, 2026 | $265.49 | $266.00 | $262.59 | $264.34 | 2.54M |
| Sep 24, 2026 | $265.37 | $267.41 | $263.09 | $265.12 | 3.46M |
| Sep 23, 2026 | $266.00 | $269.39 | $263.5885 | $265.08 | 3.47M |
| Sep 22, 2026 | $263.10 | $266.82 | $262.145 | $265.21 | 2.77M |
| Sep 21, 2026 | $263.07 | $266.5998 | $261.23 | $264.48 | 3.44M |
| Sep 18, 2026 | $263.29 | $266.34 | $262.44 | $263.96 | 8.18M |
| Sep 17, 2026 | $262.61 | $264.62 | $260.88 | $264.02 | 3.51M |
| Sep 16, 2026 | $261.99 | $264.00 | $260.975 | $262.51 | 3.12M |
| Sep 15, 2026 | $260.00 | $264.81 | $257.795 | $263.04 | 5.12M |
| Sep 14, 2026 | $261.67 | $264.6499 | $260.1001 | $261.77 | 4.51M |
| Sep 11, 2026 | $253.92 | $259.61 | $253.92 | $257.12 | 4.31M |
| Sep 10, 2026 | $251.23 | $255.31 | $249.735 | $255.00 | 4.4M |
| Sep 9, 2026 | $247.73 | $251.18 | $246.7701 | $250.91 | 3.87M |
| Sep 8, 2026 | $251.84 | $254.615 | $248.41 | $248.78 | 5.57M |
The latest Smart Investors Daily articles mentioning ABBV.
Company
Market Activity
Research & News
ABBV research
Company profile and research snapshot.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 6, 2026 | Scotiabank | Sector Outperform | — |
| Sep 10, 2026 | HSBC | Buy | — |
| Aug 20, 2026 | Piper Sandler | Overweight | — |
| Aug 17, 2026 | Wells Fargo | Overweight | — |
| Aug 13, 2026 | Wolfe Research | Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 7, 2026
A fat dividend yield means nothing if the cash runs dry before the check clears. These five companies show wildly different margins of safety, and one of them barely cleared the bar last quarter.
Yahoo · Oct 7, 2026
Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.’
Yahoo · Oct 7, 2026
IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes poised to support third-quarter 2026 growth.
Yahoo · Oct 7, 2026
Johnson & Johnson just logged its 64th straight year of dividend growth, but biosimilar threats, a MedTech slowdown, and lingering talc litigation raise a real question about whether that streak justifies buying the stock right now.
Interpretive context generated from the platform’s current data sources.
AbbVie Inc. shares closed at $266.79, reflecting a daily decline of 1.32% per SID market data. Despite the single-session pullback, the stock has demonstrated consistent upward momentum across multiple timeframes, gaining 2.13% over the past month, 4.36% over three months, and 16.61% over the trailing twelve months. Technically, ABBV trades above both key moving averages, with the current price sitting 3.42% above its 50-day moving average of $257.97 and 14.86% above its 200-day moving average of $232.26, according to SID market data. The 14-day RSI reading of 57.4 indicates neutral-to-slightly-bullish momentum without approaching overbought territory. AbbVie's beta of 0.334 underscores its low-volatility profile relative to the broader market, consistent with its defensive healthcare positioning. Average daily trading volume stands at approximately 6.4 million shares, supporting adequate liquidity for institutional participation.
AbbVie Inc. currently carries a market capitalization of approximately $410.1 billion, making it one of the largest companies in the healthcare sector, according to SID market data. The stock's trailing price-to-earnings ratio stands at 97.75, a significantly elevated figure that reflects the impact of substantial non-cash charges and amortization of acquired intangible assets on GAAP earnings. Its PEG ratio of 1.25 suggests a more moderate valuation when accounting for projected earnings growth, per SID market data. AbbVie's negative price-to-book ratio of -126.33 stems from a negative book value on the balance sheet, a consequence of extensive debt-funded acquisitions including the $63 billion Allergan deal, according to SEC filings. The company offers a dividend yield of 2.87%, maintaining its status as a Dividend Aristocrat. Investors typically evaluate AbbVie on adjusted earnings metrics rather than GAAP-based multiples to normalize for acquisition-related accounting distortions.
AbbVie Inc. registers a composite smart money score of 59 out of 100 with a neutral overall signal, according to SID market data. The institutional component scores a perfect 25 out of 25, indicating maximum confidence from large fund managers and broad-based institutional ownership. Insider activity also ranks highly at 21 out of 25, supported by two insider transactions in the past 90 days — both purchases with zero sells recorded — per SEC Form 4 filings. This unanimous insider buying pattern suggests management confidence in the company's forward trajectory. In contrast, dark pool activity scores a modest 9.6 out of 25, indicating below-average off-exchange accumulation, while congressional trading activity registers at just 3.2 out of 25, reflecting minimal recent interest from lawmakers, per 13F institutional filings. The divergence between strong institutional and insider signals versus weak dark pool and congressional activity produces the overall neutral composite reading, though the insider purchasing trend represents a constructive data point for shareholders monitoring executive sentiment.
AbbVie Inc. reported mixed recent quarterly results, with the most recently completed quarters showing narrow misses relative to consensus expectations, per company earnings reports. In the quarter reported on April 29, 2026, AbbVie posted earnings of $2.65 per share against a consensus estimate of $2.66, representing a shortfall of $0.01. The subsequent quarter reported on July 31, 2026 showed a wider miss, with actual earnings of $3.65 per share falling $0.12 below the $3.77 estimate, according to analyst estimates. Looking ahead, Wall Street expects earnings of $3.01 per share for the quarter with results anticipated on April 24, 2026, and $3.84 per share for the quarter reporting on October 30, 2026. The sequential earnings trajectory from $2.65 to a projected $3.84 reflects anticipated growth driven by AbbVie's immunology and oncology franchises, including Skyrizi and Rinvoq, which continue to offset Humira biosimilar erosion.
Wall Street consensus on AbbVie Inc. remains decisively bullish, with all five most recent analyst actions reflecting positive-to-very-positive ratings, according to Wall Street analyst reports. On October 6, 2026, Scotiabank reiterated its Sector Outperform rating, while HSBC maintained its Buy rating on September 10, 2026, per SID consensus data. Piper Sandler reaffirmed an Overweight rating on August 20, followed by Wells Fargo's Overweight reiteration on August 17. Notably, Wolfe Research upgraded ABBV to Outperform from Peer Perform on August 13, 2026, marking the sole directional change among recent coverage updates and signaling improving conviction. The unanimity of favorable ratings across five distinct firms spanning global banks and specialized healthcare research houses reflects broad institutional confidence in AbbVie's diversified revenue base. No downgrades or negative revisions appear in the recent coverage period, underscoring the consistency of the bullish analytical consensus surrounding the company's growth pipeline and commercial execution.
The latest Smart Investors Daily articles mentioning ABBV.
